Nitrolingual

prophylaxis of Angina pectoris, Congestive Heart Failure, Chest Pain + 10 more

Treatment

16 Active Studies for Nitrolingual

What is Nitrolingual

Nitroglycerin

The Generic name of this drug

Treatment Summary

Nitroglycerin is a medication used to treat chest pain and high blood pressure. It was approved by the FDA in 2000 and comes in a variety of forms, including a spray, tablets, intravenous injections, and a transdermal patch. Nitroglycerin can also be used in an ointment to ease the pain associated with anal fissures and was approved for this purpose in 1955.

Nitroglycerin

is the brand name

image of different drug pills on a surface

Nitrolingual Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Nitroglycerin

Nitroglycerin

1981

182

Effectiveness

How Nitrolingual Affects Patients

Nitroglycerin relaxes the walls of your blood vessels, allowing for increased blood flow to the heart and a decrease in the pressure of your heart's walls. This can help reduce angina symptoms. However, taking nitroglycerin for a long time can cause your body to become used to it, resulting in it becoming less effective. It may also cause problems like increased sensitivity to other substances that make your blood vessels constrict.

How Nitrolingual works in the body

Nitroglycerin works to widen your blood vessels, allowing for easier blood flow. It does this by converting to nitric oxide in smooth muscle cells. Nitric oxide activates an enzyme called guanylate cyclase, which in turn produces a compound called cyclic guanosine 3',5'-monophosphate (cGMP) in the walls of your veins, arteries, and cardiac tissue. This compound causes protein kinase-dependent phosphorylation and leads to your blood vessels relaxing, allowing for increased blood flow.

When to interrupt dosage

Condition

Dosage

Administration

Chest Pain

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Coronary Disease

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Anal Fissure

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

induction of Intraoperative Hypotension

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

insufficient response to beta-blockers

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

nitroglycerin

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Pain

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Angina Pectoris

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Congestive Heart Failure

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Hypotension

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Hypertensive disease

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

prophylaxis of Angina pectoris

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Myocardial Infarction

, 160.0 mg, 20.0 mg, 40.0 mg, 60.0 mg, 80.0 mg, 120.0 mg, 0.02 mg/mg, 0.1 mg/hour, 0.2 mg/hour, 0.4 mg/hour, 0.6 mg/hour, 2.5 mg, 9.0 mg, 6.5 mg, 0.4 mg, 0.25 mg/hour, 0.5 mg/hour, 1.0 mg/hour, 1.5 mg/hour, 0.004 mg/mg, 0.3 mg, 5.0 mg/mL, 37.4 mg, 20.8 mg, 50.0 mg, 1.0 mg, 2.0 %, 0.6 mg, 75.0 mg, 54.0 mg, 36.0 mg, 18.0 mg, 25.0 mg, 2.6 mg, 100.0 mg, 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, 0.0004 mg/mg, 18.0 mg/[USP'U], 12.5 mg, 1.0 mg/mL, 0.8 mg/hour, 7.2 mg/cm2, 0.4 mg/pump actuation, 6.0 mg/cm2

Transdermal, Patch - Transdermal, , Patch, Topical, Ointment, Ointment - Topical, Capsule, Capsule - Oral, Oral, Tablet, Sublingual, Tablet - Sublingual, Spray, Spray - Oral, Tablet - Oral, Aerosol, metered, Aerosol, metered - Sublingual, Spray, metered - Oral, Spray, metered, Rectal, Ointment - Rectal, Spray, metered - Sublingual, Tablet, orally disintegrating, Tablet, orally disintegrating - Sublingual, Injection, solution - Intravenous, Injection, solution, Intravenous, Film, extended release, Film, extended release - Transdermal, Patch, extended release, Patch, extended release - Transdermal, Liquid, Liquid - Intravenous, Solution, Solution - Intravenous, Tablet, extended release, Tablet, extended release - Oral, Buccal, Tablet, extended release - Buccal, Injection, Injection - Intravenous, Powder, Powder - Sublingual, Aerosol, spray - Transmucosal, Aerosol, spray, Injection, solution, concentrate - Intravenous, Transmucosal, Injection, solution, concentrate

Warnings

Nitrolingual Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Nitroglycerin may interact with Pulse Frequency

Cardiac Tamponade

Do Not Combine

Pulse Frequency

Do Not Combine

Hypovolemic Shock

Do Not Combine

Anemia

Do Not Combine

Pick Disease of Heart

Do Not Combine

Pulse Frequency

Do Not Combine

Acute Circulatory Failure

Do Not Combine

Intracranial Hypertension

Do Not Combine

Cardiomyopathy, Restrictive

Do Not Combine

Myocardial Infarction

Do Not Combine

There are 20 known major drug interactions with Nitrolingual.

Common Nitrolingual Drug Interactions

Drug Name

Risk Level

Description

Amediplase

Major

The therapeutic efficacy of Amediplase can be decreased when used in combination with Nitroglycerin.

Amifostine

Major

Nitroglycerin may increase the hypotensive activities of Amifostine.

Desmoteplase

Major

The therapeutic efficacy of Desmoteplase can be decreased when used in combination with Nitroglycerin.

Reteplase

Major

The therapeutic efficacy of Reteplase can be decreased when used in combination with Nitroglycerin.

Riociguat

Major

Nitroglycerin may increase the hypotensive activities of Riociguat.

Nitrolingual Toxicity & Overdose Risk

The toxic dose of nitroglycerin for rats is 105 mg/kg when taken orally and 23.2 mg/kg when taken intravenously. Overdosing on nitroglycerin can cause severe low blood pressure, headache, dizziness, rapid heartbeat, skin flushing, nausea, vomiting, shortness of breath, confusion, and paralysis. In rare cases, a condition called methemoglobinemia may occur, which can be treated with methylene blue unless a person has a known deficiency in an enzyme called G6PD. There is no known antidote for nitroglycerin overdose, so treatment involves managing the symptoms

image of a doctor in a lab doing drug, clinical research

Nitrolingual Novel Uses: Which Conditions Have a Clinical Trial Featuring Nitrolingual?

38 active trials are currently being conducted to investigate the potential of Nitrolingual to reduce the risk of Gastroesophageal variceal hemorrhage, Hypotension and Congestive Heart Failure.

Condition

Clinical Trials

Trial Phases

Coronary Disease

1 Actively Recruiting

Not Applicable

Congestive Heart Failure

11 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Pain

0 Actively Recruiting

prophylaxis of Angina pectoris

0 Actively Recruiting

Hypertensive disease

0 Actively Recruiting

induction of Intraoperative Hypotension

0 Actively Recruiting

Chest Pain

2 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Anal Fissure

1 Actively Recruiting

Phase 1

Hypotension

0 Actively Recruiting

insufficient response to beta-blockers

0 Actively Recruiting

Angina Pectoris

0 Actively Recruiting

Myocardial Infarction

0 Actively Recruiting

nitroglycerin

0 Actively Recruiting

Nitrolingual Reviews: What are patients saying about Nitrolingual?

5

Patient Review

2/11/2010

Nitrolingual for Heart Attack

I've used this product a bunch of times and it really does work well. I actually prefer it to other similar products because it doesn't take forever to dissolve and it doesn't burn my gums.

5

Patient Review

3/19/2009

Nitrolingual for Angina

4

Patient Review

6/18/2009

Nitrolingual for Angina

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about nitrolingual

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is nitrolingual the same as nitroglycerin?

"Nitrolingual Pumpspray is a nitrate that dilates blood vessels, making it easier for blood to flow through them. It is used to treat or prevent attacks of chest pain."

Answered by AI

How many times a day can you use nitro spray?

"Adults should take 2.5 to 6.5 mg of medication 3 to 4 times a day. If needed, a doctor may increase the dose."

Answered by AI

How long does nitrolingual spray take to work?

"It typically takes 1-3 minutes for the tablets to take effect, and the spray 1-3 minutes as well. To use the spray, administering 1-2 sprays under the tongue before beginning the desired activity."

Answered by AI

What is nitrolingual spray used for?

"This medication is used to relieve chest pain in people that have a certain heart condition. It may also be used before physical activities to help prevent chest pain. Nitroglycerin belongs to a class of drugs known as nitrates."

Answered by AI

Clinical Trials for Nitrolingual

Image of Mumford Professional Centre in Halifax, Canada.

Remote Monitoring for Cardiovascular Disease

18+
All Sexes
Halifax, Canada

The goal of this interventional study is to evaluate the implementation, usability, and clinical outcomes of a wearable medical-grade device in a virtual Cardiac Rehabilitation (CR) program, titled HEARTS in Sync. The question guiding this study is: Do patient clinical outcomes differ between those who use the CardioWatch 287-2 during the HEARTS in Sync program as compared to those who participate without using the CardioWatch 287-2? The comparison will happen between two non-randomized groups of patients who are enrolled in the HEARTS in Sync virtual CR program. The wearable device (CardioWatch 287-2), worn on patient's wrists, will provide clinicians with physiological information to better mirror the clinical oversight provided to an in-person CR program. Participants who choose to use the device will be asked to wear it daily. The clinical team will review weekly summary reports to help guide participant progress through the 13-week program. The primary objectives of this study are to: 1. Characterize participants (e.g., demographic health history, patient feedback) between those who choose to use the CardioWatch 287-2 device and those who do not. 2. Compare clinical outcomes between users and non-users of the device within the HEARTS in Sync program, by: 1. Tracking patient enrollment, attendance in virtual education sessions, and program completion rates, 2. Evaluating change in patient bloodwork outcomes, 3. Measuring change is physical ability, 4. Analyzing changes in eating behaviours, and 5. Examining quality of life using validated tools. 3. Asses the feasibility of the CardioWatch 287-2 for the HEARTS in Sync virtual CR program by: 1. Assessing device adherence 2. Reviewing patient feedback survey, and 3. Determining if clinician team were able to access and interpret data collected throughout the program The secondary objective of this study is to compare clinical outcomes of device users during the HEARTS in Sync program with patients who completed the on-site CR program. This research aims to better understand how a medical-grade device may improve virtual CR programming to extend clinical care to the community. As a result, this could lead to a more personalized care and better results for patients.

Waitlist Available
Has No Placebo

Mumford Professional Centre

Nicholas B Giacomantonio, Medical Doctor

Corsano Health B.V.

Image of Virginia Commonwealth University in Richmond, United States.

Endovascular Treatment for Stroke

18+
All Sexes
Richmond, VA

Endovascular therapy (EVT) has proven to be more beneficial for patients with AIS caused by large vessel occlusions (LVO) than medical management alone. A recent meta-analysis of 5 RCTs showed that EVT significantly reduced disability at 90 days compared to medical management \[1\]. Despite its obvious benefits, patients may have neurological deterioration despite successful thrombectomy due to ischemia progression, intracranial hemorrhage, re-occlusion, or vasogenic edema. The incidence of early neurological deterioration (END) following EVT for acute stroke has been reported to be ranging from 14.1-35.2% with some studies defining END up to 7 days and some restricting the definition between 6-72 hours post thrombectomy. A small proportion of these patients, approximately 5.9-10.5%, experienced sICH following EVT. Whether END occurs due to ischemic or hemorrhagic it leads to worse outcomes.

Waitlist Available
Has No Placebo

Virginia Commonwealth University

Aarti Sarwal

Have you considered Nitrolingual clinical trials?

We made a collection of clinical trials featuring Nitrolingual, we think they might fit your search criteria.
Go to Trials
Image of University of Tennessee Medical Center in Knoxville, United States.

Pharmacy Intervention for Medication Adherence

18+
All Sexes
Knoxville, TN

Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.

Recruiting
Senior-friendly

University of Tennessee Medical Center (+1 Sites)

Satya Surbhi, PhD

Image of Brigham and Women's Hospital in Boston, United States.

Care Transitions App for Multiple Chronic Conditions

18+
All Sexes
Boston, MA

The objective of this study is to widely implement and evaluate the Care Transitions App in a randomized controlled trial. The app the investigators designed for patients with multiple chronic conditions has four envisioned modules: 1) falls-reduction content, 2) a digital post-discharge transitional care plan (e.g., after hospital care plan, including education, medications, follow-up appointments, warning signs to watch for, nutrition, and other care plan activities), 3) a new module for patients with MCC (diabetes, congestive heart failure, and chronic kidney disease) including condition-specific post-discharge care plans with relevant symptom management activities, 4) a new post-discharge report module which summarizes key care transition findings and allows for patients to enter notes and questions for their providers and their own goals for recovery.

Recruiting
Has No Placebo

Brigham and Women's Hospital

Lipika Samal, MD, MPH

Have you considered Nitrolingual clinical trials?

We made a collection of clinical trials featuring Nitrolingual, we think they might fit your search criteria.
Go to Trials
Image of Columbia University Medical Center/ NewYork Presbyterian Hospital in New York, United States.

CTO PCI for Chronic Total Occlusions

18+
All Sexes
New York, NY

Following unsuccessful CTO crossing a CTO modification procedure is sometimes performed. CTO PCI registries where plaque modification has been performed in some patients, report this to be safe, and associated with higher success rates at subsequent attempts. It has never been investigated whether a planned investment procedure, with an intention that both the initial and staged completion PCI are of shorter duration, could improve safety and efficacy. The investigators hypothesize that 1. A planned investment procedure in the treatment of CTOs will be associated with improved patient safety 2. A planned investment procedure will be associated with improved cumulative procedure success rates 3. A planned two stage procedure will be associated with improved patient experience

Waitlist Available
Has No Placebo

Columbia University Medical Center/ NewYork Presbyterian Hospital

Margaret B Mcentegart, PhD

Have you considered Nitrolingual clinical trials?

We made a collection of clinical trials featuring Nitrolingual, we think they might fit your search criteria.
Go to Trials